Cargando…
De novo bronchiectasis in haematological malignancies: patient characteristics, risk factors and survival
Bronchiectasis occurs de novo in haematological malignancy and is associated with significant mortality and morbidity. Rituximab predisposes to IgG deficiency and survival time is significantly associated with age, FEV(1) % and stem cell transplantation. http://bit.ly/2KZwCZt
Autores principales: | José, Ricardo J., Hall, Jocelin, Brown, Jeremy S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826250/ https://www.ncbi.nlm.nih.gov/pubmed/31720297 http://dx.doi.org/10.1183/23120541.00166-2019 |
Ejemplares similares
-
Survival of critically ill patients with haematological malignancies compared with patients without haematological malignancy
por: Pugh, R, et al.
Publicado: (2013) -
Voriconazole associated torsades de pointes in two adult patients with haematological malignancies
por: Brown, Jeremy D., et al.
Publicado: (2014) -
BURDEN OF CARE IN PARENTS OF CHILDREN SUFFERING FROM HAEMATOLOGICAL MALIGNANCIES
por: Ashok, M.V., et al.
Publicado: (1998) -
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union
por: Polsinelli, Benedetta, et al.
Publicado: (2017) -
Characteristics and Follow-Up of Organizing Pneumonia Associated with Haematological Malignancies
por: Zeng, Huihui, et al.
Publicado: (2022)